Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney Disease Plans to Initiate Rare Kidney Diseases Cohort in Early 2025 Company to Attend 43rd Annual J.P. Morgan ...

More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...

The fires, which are still not under control and have killed at least five people, are likely to cost more than $50 billion in overall losses, the analysts said. Late Thursday, Accuweather pinned the ...

JPMorgan Income ETF’s JPIE experienced, specialized, and collaborative team earned it a People Pillar rating boost to High, ...

A preliminary report by Accuweather estimated the cost of the wildfires ravaging L.A. County at more than $50 billion, a ...

The Los Angeles wildfires are now expected to exceed $20B, J.P. Morgan analyst Jimmy Bhullar estimated Thursday, doubling his ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

Saudi Arabia’s Public Investment Fund (PIF) has invested US$200 million in a Saudi bond exchange-traded fund managed by State ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

FY2024 revenue up 7% YoY, driven by international demand. Find out why I am upgrading CTKB stock from Hold to Buy.